Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin

Matthieu Million; Audrey Giraud-Gatineau; Jean-Christophe Lagier; Philippe Parola; Philippe Gautret; Didier Raoult

doi:10.1016/j.tmaid.2020.101954

Journal articles

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin

Matthieu Million ¹ Audrey Giraud-Gatineau ² Jean-Christophe Lagier ¹ Philippe Parola ² Philippe Gautret ² Didier Raoult ¹

1 MEPHI - Microbes évolution phylogénie et infections

2 VITROME - Vecteurs - Infections tropicales et méditerranéennes

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Microbiology and Parasitology / Bacteriology

Life Sciences [q-bio] / Microbiology and Parasitology / Virology

Life Sciences [q-bio] / Microbiology and Parasitology / Parasitology

Life Sciences [q-bio] / Human health and pathology / Cardiology and cardiovascular system

Life Sciences [q-bio] / Human health and pathology / Emerging diseases

Life Sciences [q-bio] / Human health and pathology / Infectious diseases

Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03211439
Contributor : Isabelle Combe <>
Submitted on : Wednesday, April 28, 2021 - 5:00:09 PM
Last modification on : Thursday, April 29, 2021 - 3:22:28 AM

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin

Links full text

Identifiers

Collections

Citation

Export

Metrics

19

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

19